Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A fixed-dose topical combination of microencapsulated benzoyl peroxide (3%) and microencapsulated tretinoin (0.1%), developed for the treatment of acne vulgaris. Benzoyl peroxide acts as an anti-infective and oxidant with keratolytic properties, while tretinoin is a retinoid that functions as a retinoic acid receptor agonist to modulate epithelial cell growth and differentiation. The formulation uses Sol-Gel Technologies' proprietary microencapsulation technology to enhance stability and tolerability. The product is marketed under the brand name Twyneo for use in patients aged 9 years and older[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzoyl peroxide + tretinoin.